Abcuro, Inc.
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis (NCT06450886) | Abcuro, Inc. | 2024-10-21 |
| A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis (NCT05721573) | Abcuro, Inc. | 2023-02-28 |
| ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) (NCT05532722) | Abcuro, Inc. | 2022-09-28 |
| A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) (NCT04659031) | Abcuro, Inc. | 2021-05-25 |
Track Abcuro, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.